Trusted Resource for Clinical Trials, Protocols & Progress
Once a Phase 3 clinical trial successfully demonstrates safety and efficacy, attention shifts to commercial readiness. Bringing a product to market is not just about regulatory approval—it’s about ensuring access, reimbursement, pricing, and uptake in target geographies.
Click to read the full article.
In certain life-threatening or rare conditions, patients may exhaust all approved treatment options while new drugs are still under regulatory review or in early commercialization stages. That’s where Expanded Access (EA) and Compassionate Use (CU) programs come in—providing critically ill individuals with investigational or recently approved therapies under defined regulatory pathways. These programs often operate under the umbrella of Phase 4 clinical activities, serving both public health and research interests.
Click to read the full article.
Phase 2 clinical trials often explore multiple endpoints, treatment arms, biomarkers, or dose levels to evaluate a drug’s efficacy and safety. However, this multidimensional approach can introduce a major statistical issue—multiplicity. When multiple hypotheses are tested simultaneously, the risk of false-positive results increases. At the same time, interim analyses are frequently built into Phase 2 designs to allow early decisions. This tutorial explores best practices for managing both multiplicity and interim analyses in Phase 2 trials to ensure valid, interpretable, and regulatorily acceptable results.
Click to read the full article.
Long-acting injectables (LAIs) are a rapidly growing therapeutic platform offering sustained drug release and improved patient adherence across a range of indications—from mental health and contraception to infectious diseases and metabolic disorders. However, evaluating LAIs in early-phase trials introduces unique pharmacokinetic, safety, and ethical challenges. Phase 1 studies of LAIs must balance prolonged exposure risks, depot kinetics, and delayed adverse events, often requiring specialized designs and real-time monitoring. This tutorial explores the complexities of designing Phase 1 studies for long-acting injectable drugs and outlines strategies for mitigating dosing and safety risks.
Click to read the full article.
Real-World Data (RWD) refers to data collected from routine healthcare settings, outside the controlled environment of traditional clinical trials. This includes:
Click to read the full article.
When a drug is approved and commercialized, its reach often spans multiple countries and continents. This introduces diverse populations, prescribing behaviors, genetic backgrounds, comorbidities, and regulatory requirements. To manage the complexity of global use, Multinational Post-Marketing Surveillance (PMS) Programs are launched as part of Phase 4 clinical trial strategies. These programs ensure that safety and effectiveness are continuously monitored in real-world settings across multiple jurisdictions.
Click to read the full article.
One of the most critical junctures in drug development occurs at the end of a Phase 2 trial—deciding whether to advance a candidate to Phase 3. This decision, often referred to as a “Go/No-Go” decision, involves a thorough evaluation of safety, efficacy, pharmacokinetics, pharmacodynamics, and strategic considerations. A well-defined decision framework helps ensure objectivity, minimizes bias, and avoids the costly mistake of proceeding with a product that lacks sufficient evidence of benefit. This tutorial outlines the key components, methodologies, and best practices for defining and executing Go/No-Go decisions in Phase 2 clinical trials.
Click to read the full article.
Phase 1 clinical studies are traditionally viewed as safety and pharmacokinetics (PK)-focused investigations, but they also form the backbone of any successful New Drug Application (NDA) or Biologics License Application (BLA). Regulatory agencies such as the FDA, EMA, and CDSCO closely examine Phase 1 data to assess the scientific justification for proposed dosing regimens, identify safety signals, and evaluate the overall benefit-risk profile. This tutorial provides a comprehensive look at how Phase 1 results are used in regulatory submissions and what regulators expect when reviewing this data.
Click to read the full article.
Post-hoc analyses refer to analyses that are conducted after the primary results of a clinical trial have been reviewed—usually not pre-specified in the protocol or statistical analysis plan (SAP). In the context of Phase 3 trials, post-hoc analyses allow researchers to explore additional insights, generate new hypotheses, or investigate unexpected findings.
Click to read the full article.
As precision medicine gains traction, the focus of drug development and surveillance has shifted beyond one-size-fits-all approaches. Pharmacogenomics—the study of how genetic variations influence drug response—plays a critical role in optimizing treatment outcomes and minimizing adverse drug reactions (ADRs). In Phase 4 clinical trials, pharmacogenomic research helps identify real-world genetic risk populations, adverse event susceptibilities, and dose optimization strategies.
Click to read the full article.
